We report the case of a 75-year old woman who received sorafenib (Nexavar (R), Bayer Pharmaceuticals Corporation, West Haven, CT) for a CNS relapse of clear cell renal cell carcinoma. After four months of sorafenib treatment, a brain magnetic resonance imaging showed 95%-volumetric regression of cerebral metastasis. To the best of our knowledge, this is the first almost complete resolution of brain metastases in renal cell carcinoma treated with sorafenib that has been described.
Long-lasting successful cerebral response with sorafenib in advanced renal cell carcinoma
Valcamonico, Francesca;Ferrari, Vittorio;Amoroso, Vito;Simoncini, Edda;Grisanti, Salvatore;
2008-01-01
Abstract
We report the case of a 75-year old woman who received sorafenib (Nexavar (R), Bayer Pharmaceuticals Corporation, West Haven, CT) for a CNS relapse of clear cell renal cell carcinoma. After four months of sorafenib treatment, a brain magnetic resonance imaging showed 95%-volumetric regression of cerebral metastasis. To the best of our knowledge, this is the first almost complete resolution of brain metastases in renal cell carcinoma treated with sorafenib that has been described.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Valcamonico et al. J Neurooncol. 2008.pdf
solo utenti autorizzati
Tipologia:
Full Text
Licenza:
Creative commons
Dimensione
327.15 kB
Formato
Adobe PDF
|
327.15 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
